Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMK8SY6)

Drug Name
E2027 Drug Info
Indication
Disease Entry ICD 11 Status REF
Lewy body dementia 6D82 Phase 2 [1]
Parkinson disease 8A00.0 Phase 2 [1]
Alzheimer disease 8A20 Phase 1 [2]
Cross-matching ID
PubChem CID
136253996
TTD Drug ID
DMK8SY6

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 9 (PDE9) TTZOEBC PDE9A_HUMAN Antagonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Phosphodiesterase 9 (PDE9) DTT PDE9A 1.807 8.131 3.263 2.7
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Lewy body dementia
ICD Disease Classification 6D82
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Phosphodiesterase 9 (PDE9) DTT PDE9A 8.73E-03 0.07 0.36
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04764669) A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)